Skip to main content

Advertisement

Table 4 Drugs targeting inflammatory immune cells in the tumour microenvironment of solid tumours (excluding haematological cancers)

From: Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia

CT identifier Drug Method of action Cancer Approved/phase study
Targeting T lymphocytes
NCT01844505 Nivolumab Anti-PD1 mMM Phase 3
NCT01642004 Nivolumab Anti-PD1 NSCLC Phase 3
NCT01354431 Nivolumab Anti-PD1 mRCC Phase 2
NCT00094653 Ipilimumab Anti-CTLA4 mMM Approved
NCT00861614 Ipilimumab Anti-CTLA4 PC Phase 3
NCT01450761 Ipilimumab Anti-CTLA4 SCLC Phase 3
NCT01285609 Ipilimumab Anti-CTLA4 NSCLC Phase 3
NCT01693783 Ipilimumab Anti-CTLA4 Cervical cancer Phase 2
NCT01860430 Ipilimumab Anti-CTLA4 HNSCC Phase 1B
NCT00257205 CP-675,206 Anti-CTLA4 mMM Phase 3
Blocking immune cell recruitment
NCT01346358 IMC-CS4 CSFR1 antagonist Advanced tumours Phase 1
NCT01316822 ARRY-382 CSFR1 antagonist Advanced tumours Phase 1
NCT01015560 MLN1202 Anti-CCR2 Bone metastases Phase 1
NCT01032122 Rituximab Anti-CD20 mMM Phase 1
NCT01376713 Ofatumumab Anti-CD20 mMM Phase 2
NCT01456585 CP-870,893 Anti-CD40 mPC Phase 2
NCT01103635 CP-870,893 Anti-CD40 mMM Phase 1
NCT00607048 CP-870,893 Anti-CD40 Solid tumours Phase 1
Reprogramming immune cells
NCT00169104 G-CSF Sustained neutrophilia mBC Phase 1/2
NCT00014456 G-CSF   Solid tumours Phase 1
NCT00070629 Promune TLR9 agonist NSCLC Phase 2
NCT00043394 Promune TLR9 agonist BC Phase 2
NCT00070642 Promune TLR9 agonist MM Phase 2
NCT00043407 Promune TLR9 agonist RCC Phase 1/2
NCT00292045 Promune TLR9 agonist PC Phase 1
NCT00669292 Promune TLR9 agonist Esophageal cancer Phase 1/2
Multiple Vaccines (Multiple targets) T-cell activation Multiple cancers  
TH2-- > TH1 reprogramming
NCT01642290 Anti-OX40 Anti-OX40 mBC Phase 1/2
NCT01644968 Anti-OX40 Anti-OX40 Advanced cancer Phase 1
NCT01689870 Anti-OX40 Anti-OX40 mMM Phase 1/2
  1. For an indepth review of the current landscape of targeting chronic inflammation, see Coussens [9]. CT identifier is to clinicaltrials.gov.
  2. Abbreviations: mMM metastatic malignant melanoma, NSCLC non-small cell lung cancer, mRCC metastatic renal cell carcinoma, PC prostate cancer, SCLC small-cell lung cancer, HNSCC head-and-neck squamous cell cancer, mBC metastatic breast cancer.